Germany, SloveniaSlovenia

Pliva expands into German oncology market

24.10.2007

Zagreb – Barr-PLIVA d.d.’s German subsidiary AWD.pharma GmbH & Co. KG. has signed an agreement to acquire O.R.C.A.pharm GmbH (“ORCApharm“), a privately owned specialty pharmaceutical company focused on the oncology market in Germany. Upon closing of the transaction, AWD will pay a fixed purchase price of €21million and up to an additional €13million based on the fulfillment of milestones for 2007 and 2008.

“Our acquisition of ORCApharm, a well established player in the German oncology market, provides us with a strategic platform for entering the highly lucrative oncology business in Germany and strongly supports our corporate strategy of focusing on markets with greater barriers-toentry and thus greater value,” commented Željko Covic, President of Pliva’s Management Board and COO. The acquisition of ORCApharm and its current product portfolio supports Pliva’s commitment to the European oncology market, said Covic. ”It strengthens the foothold we have already established through our Czech subsidiary Pliva Lachema, which focuses on the development, production and distribution of vertically integrated injectable cytostatic products. Furthermore, we are confident that we will deliver additional product synergies by expanding ORCA’s portfolio to include select Pliva and Barr products that complement oncology treatments, such as our pain and CNS franchises.” Pliva, the European subsidiary of Barr Pharmaceuticals, also is developing generic versions of biological drugs such as Neupogen. It develops a GCSF biosimilar for treatment of neutropenia after cancer chemotherapy.
In the first six months of this year, Pliva achieved revenues of €560 million, which was lifted by a one-off payment of €109 million for its subsidiary in the US, which it sold to Barr in April. Pliva‘s pre-tax income quadrupled to €177 million and net profit tripled to €150 billion.

SloveniaSlovenia

12.08.2005

Zagreb - Croatia's Government passed a new law on genetically modified organisms (GMO), which replaces the “biotechnology-regulating provisions” of the Law on the Protection of Nature that up to now regulated the importation,...

SloveniaSlovenia

10.07.2005

Ljubljana - Slovenian pharma company Pharmaswiss and Swiss pharma group Helsinn Healthcare SA have signed a licensing agreement granting Pharma-swiss the exclusive license and distribution rights for ALOXI®, a strong and...

SloveniaSlovenia

10.07.2005

Brac - The “Fall 2005 Course on Bioprocess Engineering”, organized by the EFB's Working Group on Bioreactor Performance in collaboration with the European Section on Biochemical Engineering Science, will be held from September...

SloveniaSlovenia

05.02.2005

Zagreb - The 4th International Conference on “Biotechnology and Immunomodulatory Drugs” will open its gates from February 20-23, 2005, in Zagreb, Croatia. Organized amongst others by the Croatian Society of Biotechnology and...

SloveniaSlovenia

09.10.2004

Ljubljana - Slovenia's supreme court has rejected an appeal by US-drug group Merck & Co. Inc. in August, ending a 10-year patent dispute with local drug maker Krka d.d. over one of its best-selling drug. The court rejected a...

SloveniaSlovenia

06.08.2004

Opatija - Nutrition-related biotechnology has been subject to many controverse public debates lately. The organizers of the “2nd Central European Meeting - 5th Croatian Congress of Food Technologists, Biotechnologists und...

SloveniaSlovenia

09.04.2004

Ljubljana - BIA Separations, specialized in the short monolithic column technology, will hold the “First Summer School on Monoliths for Biochro-matography, Bioconversion, and So-lid Phase Synthesis” in Potoroz, Slo-venia, from...

SloveniaSlovenia

05.03.2004

Menges - Lek Pharmaceuticals inaugurated a new manufacturing plant (PORT1) for the production of biopharmaceuticals - such as human proteins for therapeutic applications - near the Slovenian capital Lubljana in Menges in early...

SloveniaSlovenia

05.02.2004

Ljubljana - Slovenian pharmaceutical company Lek d.d. successfully defended in late December its patent EP 1 095 037, which covers Lek's synthesis of Ome-prazole before the Board of Appeal of the European Patent Office....

SloveniaSlovenia

23.11.2003

Ljubljana - Scientists at the Department of Biochemistry and Molecular Biology, Jozef Stefan Institute, Ljubljana, have identified an intracellular membrane receptor for a snake venom secretory phospholipase A (sPLA). The...

Displaying results 11 to 20 out of 22

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-slovenia/browse/1/article/pliva-expands-into-german-oncology-market.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.51 CHF12.14%
  • STRATEC BIOMEDICAL41.09 EUR4.55%
  • MEDIGENE4.00 EUR2.30%

FLOP

  • CYTOS0.18 CHF-5.26%
  • MOLOGEN6.60 EUR-2.22%
  • SANTHERA86.95 CHF-1.92%

TOP

  • PAION3.22 EUR33.6%
  • CO.DON3.14 EUR27.6%
  • FORMYCON8.20 EUR16.3%

FLOP

  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.10 EUR-16.7%
  • MOLOGEN6.60 EUR-12.8%

TOP

  • SANTHERA86.95 CHF2146.8%
  • PAION3.22 EUR238.9%
  • CO.DON3.14 EUR223.7%

FLOP

  • CYTOS0.18 CHF-95.3%
  • MOLOGEN6.60 EUR-44.5%
  • 4SC1.04 EUR-44.4%

No liability assumed, Date: 01.10.2014


Current issue

All issues

Product of the week

Products